Subscribe
Piotr Swat / Shutterstock.com
3 December 2024NewsAmericasMarisa Woutersen

Amgen faces pushback over bid to narrow patent scope

German biotech asks federal judge to reject Amgen’s efforts to narrow scope of a key patent in ongoing dispute | Patent relates to Lindis' cancer immunotherapy treatment | Lindis calls on court to uphold the broader interpretation and claims Amgen’s attempt to narrow is inconsistent with the patent's history.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024   Regeneron loses bid to block Eylea copy at US appeals court | Biotech says decision ‘not the final word’ in litigation
Americas
Court denies Regeneron bid to halt copy of blockbuster eye drug
24 September 2024   Biotech’s motion for preliminary injunction to prevent Eylea biosimilar rejected I Regeneron has filed multiple suits over rivals’ copies of aflibercept.


Editor's picks

Americas
Comparing life sciences IP in Brazil and the US
28 November 2024

Editor's picks

Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024

More on this story

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024   Regeneron loses bid to block Eylea copy at US appeals court | Biotech says decision ‘not the final word’ in litigation
Americas
Court denies Regeneron bid to halt copy of blockbuster eye drug
24 September 2024   Biotech’s motion for preliminary injunction to prevent Eylea biosimilar rejected I Regeneron has filed multiple suits over rivals’ copies of aflibercept.

More on this story

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024   Regeneron loses bid to block Eylea copy at US appeals court | Biotech says decision ‘not the final word’ in litigation
Americas
Court denies Regeneron bid to halt copy of blockbuster eye drug
24 September 2024   Biotech’s motion for preliminary injunction to prevent Eylea biosimilar rejected I Regeneron has filed multiple suits over rivals’ copies of aflibercept.

More features

LSPN Europe: Navigating the EPO and lessons from the UPC frontline
Paul Hastings reinforces London office with high-tech patent litigator
Gene tech firm fends off injunction in test kit dispute
Comparing life sciences IP in Brazil and the US
Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings